The acquisition strengthens Bausch + Lomb's existing portfolio of surgical and pharmaceutical glaucoma treatments.

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to ...

Bausch + Lomb announced today that an affiliate acquired Elios Vision, developer of a minimally invasive glaucoma surgery ...

Bausch + Lomb announced today that, in response to a request from regulatory authorities, it authorized the exploration of a ...

Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating ...

Bausch + Lomb Corp (NYSE:BLCO) shares tumbled more than 12% on Wednesday in New York Stock Exchange after report that ...

This strategic move expands Bausch + Lomb’s glaucoma treatment portfolio, which already encompasses pharmaceutical and surgical solutions. Luc Bonnefoy, president of Surgical at Bausch + Lomb ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an ...

Bausch + Lomb (BLCO) announced that an affiliate has acquired Elios Vision, developer of the ELIOS procedure, the first clinically validated, ...

The acquisition strengthens Bausch + Lomb's existing portfolio of surgical and pharmaceutical glaucoma treatments. Leerink Partners acted as exclusive financial adviser to Elios Vision for the ...

VAUGHAN, Ontario - Bausch + Lomb Corporation (NYSE/TSX: BLCO), a prominent eye health company trading near its 52-week high of $21.69, today announced the acquisition of Elios Vision, Inc., the ...